JPS6034914A - Food containing extract of ganodema licidum - Google Patents
Food containing extract of ganodema licidumInfo
- Publication number
- JPS6034914A JPS6034914A JP58144018A JP14401883A JPS6034914A JP S6034914 A JPS6034914 A JP S6034914A JP 58144018 A JP58144018 A JP 58144018A JP 14401883 A JP14401883 A JP 14401883A JP S6034914 A JPS6034914 A JP S6034914A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- licidum
- ganodema
- solvent
- hot water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
この発明は霊芝抽出物Qこ係り、その1目1的は霊芝抽
出物を食品に含有させることによってこの食品を摂食す
る摂食者の炎症、血栓、策心症、動脈硬化、アレルキー
等の多くの病体の原因物質であるアラキドン酸代謝物の
抑制効■↓やあるいは高脂血症等の症状をもたらす血液
粘度を低下させることができる食品の提供にある。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to Reishi mushroom extract Q, and its first objective is to prevent inflammation, blood clots, and preventive measures for those who consume this food by including Reishi mushroom extract in food. Our goal is to provide foods that can suppress arachidonic acid metabolites, which are causative agents of many diseases such as heart disease, arteriosclerosis, and allergies. .
霊芝(Ganodenna licidum )はザJ
L/ / :+ シカヶ類O″−属するキノコの一種で
、従来からこの霊芝は民間薬として多用されてきたもの
であって、特に肝機能の改善や近年Oこおいてはその熱
水抽出物であるヘミセルローヌ化合物の抗がん作用が着
1」されているキノコである。Ganodenna licidum is the J.
L/ / :+ A type of mushroom belonging to the genus O''-, this reishi mushroom has traditionally been widely used as a folk medicine, especially for improving liver function and in recent years, its hot water extraction has been used. This mushroom is known for its anti-cancer properties due to its hemicellrone compound.
この発明者らはこの霊芝の抽出物Qこついて長年Oこ亙
り鋭意研究を続けたところ、この霊芝の特定抽出法に基
づく抽出1勿が血清中のアラキドン酸の代謝を抑制し、
また、血液粘度を低下させて高面圧症、高脂血症、肝炎
、糖尿病、不定愁訴症候群等の血液高粘度によってもた
らせる症候を改善することを見い出しこの発明に至った
ものである。The inventors continued intensive research for many years on this Reishi mushroom extract Q, and found that extract 1 based on a specific extraction method of Reishi mushroom suppresses the metabolism of arachidonic acid in serum.
Furthermore, the inventors have discovered that symptoms caused by high blood viscosity, such as hypertension, hyperlipidemia, hepatitis, diabetes, and indeterminate complaint syndrome, can be improved by lowering blood viscosity, leading to the present invention.
この発明はすなわち霊芝(Ganoderma lic
idum)の熱水抽出物を更に含酸素系有機溶媒で抽出
した抽出物を必須成分とする霊芝抽出物を含有する食品
に関わるものである。This invention is based on Ganoderma lic.
The invention relates to a food containing a Reishi mushroom extract whose essential ingredient is an extract obtained by further extracting a hot water extract of M. idum with an oxygen-containing organic solvent.
この発明において使用する霊芝抽出物は、例えば霊芝を
乾燥させこの乾燥させた霊芝100.7をスライスまた
ミンチ状で裁断しこの裁断した霊芝を60℃〜70℃程
度の温水で霊芝100!I+こ対し水11程度を加え1
〜2時間程度抽出し、この抽出液を戸別し、熱水抽出物
を得る。The Reishi mushroom extract used in this invention can be obtained by, for example, drying Reishi mushrooms, cutting the dried Reishi mushrooms into slices or minced pieces, and soaking the cut Reishi mushrooms in hot water at about 60°C to 70°C. Shiba 100! Add about 11 parts of water to I + 1
Extraction is carried out for about 2 hours, and the extract is distributed from person to person to obtain a hot water extract.
更に、この熱水抽出物の乾燥粉末50,7程度(二対し
含酸素系有機溶媒としてアセトンを使用し、このアセト
ン(11)で抽出しこの抽出操作を2回反復してこのア
セトン可溶分を戸別し、このF液を濃縮乾固あるいはア
セトンのみを揮散した水溶液とすればよい。Furthermore, dry powder of this hot water extract (about 50.7%) was extracted with acetone (11) using acetone as the oxygen-containing organic solvent, and this extraction operation was repeated twice to remove the acetone soluble content. The solution F may be concentrated to dryness or made into an aqueous solution with only acetone volatilized.
この発明Qこおいては特に霊芝抽出物が熱水抽出後さら
)二含酸素系有機溶媒で抽出した抽出物とした場合に、
従来知られている霊芝抽出物が熱水抽出処理しただけの
抽出物である場合やこの熱水抽出物の含酸素系有機溶媒
不溶分の水可m抽出物である場合に較べて特Oこ有効な
効用を発揮することがこの発明者らの実験的知得によっ
て明らかQこなったものである。In this invention Q, especially when the Ganoderma extract is extracted with hot water and further extracted with a dioxygenated organic solvent,
Compared to cases where conventionally known Ganoderma extracts are extracts that have only been subjected to hot water extraction treatment or are water-soluble extracts of the oxygen-containing organic solvent insoluble portions of this hot water extract, It has been clearly demonstrated through the experimental knowledge of the inventors that this effective effect can be exerted.
この発明で好適に使用できる含酸素系育成溶媒としては
、アセトン、メチルエチルケトン等のケトン系溶媒、エ
チルエーテル、メチラール等のエーテル71% 溶媒+
メチルアルコール、エチルアルコール等のアルコール
系溶媒等が好適に使用できる。Oxygen-containing growth solvents that can be suitably used in this invention include ketone solvents such as acetone and methyl ethyl ketone, and 71% ether solvents such as ethyl ether and methylal.
Alcohol solvents such as methyl alcohol and ethyl alcohol can be suitably used.
このような方法で得られた霊芝抽出物をこの発明に係る
食品形状とするOこは通常、J、!(食者が11」3.
000mg〜9,000mg摂食できるような状態の散
剤あるいは清涼飲料水あるいは他の任意の食品形態とす
ればよい。The Reishi mushroom extract obtained by such a method is usually used in the form of food according to the present invention. (The eater is 11"3.
000mg to 9,000mg can be taken as a powder, soft drink, or any other food form.
次にこの発明に係る実施例並びQこ試験例を示すことに
よってこの発明の効果をより一層明らかなものとする。Next, the effects of the present invention will be made clearer by showing examples and test examples according to the present invention.
実施例
霊芝11cgを調製し、この霊芝11cgを乾燥させた
後5 mm程度の肉厚で裁断した後60メツンユAスの
粉末状に粉砕した。Example 11 cg of Ganoderma lucidum was prepared, dried, cut into pieces with a thickness of about 5 mm, and then ground into a powder of 60 mm.
次Oここの霊芝を70℃の温水で霊芝100.!7iこ
対し水11を加え2時間抽出しこの抽出液を戸別り残在
とF液を分離した残在を取り出し更Oこミンチ状に粉砕
し、このミンチ状に粉砕した霊芝をさらにl’の水を加
え3時間程度70℃程度に加温して抽出操作を行い、前
記の抽出液と加える。Next Reishi 100% in warm water of 70℃. ! Add 11 parts of water to the 7 parts and extract for 2 hours. The extract is separated from the remaining part of the liquid F. Take out the remaining part and grind it into minced pieces. water is added thereto, heated to about 70°C for about 3 hours to perform an extraction operation, and then added to the above-mentioned extract solution.
尚、減圧状態でこのF液を5笈縮した。Note that this F solution was compressed by 5 liters under reduced pressure.
このようにして得た熱水抽出物(50g但し粉末重敬)
をアセトン可溶分に添加し、1時間抽出しその後混合物
を戸別し残在に更に11のアセトンを加え同一条件で攪
拌混合抽出した。Hot water extract obtained in this way (50g, but powdered)
was added to the acetone soluble matter and extracted for 1 hour.Then the mixture was taken from house to house and 11 acetones were further added to the residue and extracted with stirring under the same conditions.
この攪拌混合物も戸別し両方のアセトン抽出物のP液を
集め、このF液を減圧乾燥させて784gのアセトン抽
出物を得た。This stirred mixture was also sent door to door, and the P solution of both acetone extracts was collected, and the F solution was dried under reduced pressure to obtain 784 g of acetone extract.
比較例
実施例中の戸別されたアセトン不溶分を集めこのアセト
ン不溶分Qこ対し常温状態で400ゴの水を加え、この
水中Gこ攪拌混合して水可m分を得た。Comparative Example The acetone-insoluble matter collected from each household was collected, and to the acetone-insoluble matter Q, 400 g of water was added at room temperature, and the water was stirred and mixed to obtain a water-soluble m portion.
この状態で、P液を蒸発乾固し37,7の水可溶分を得
た。In this state, the P solution was evaporated to dryness to obtain a water-soluble component of 37.7.
試験例1
ウィスターキング系オスラノ1−(250〜350g)
を使用し、このラット血液を採取した。Test Example 1 Wistar King Oslano 1- (250-350g)
This rat blood was collected using
このラット血液Oこ対し抗凝固剤としてEDTAを5.
8 mM加えその後この血液を2201で室温で10分
間遠心分離機にかけその上ずみ(多血小板血漿)を更)
こi、5oox、yで10分間遠心分離した。この状態
で得た血小板を2mMEGTAを含むHEPES−生理
食塩水緩衝液(25mMHEPES、l35mM Na
C1,PH7,4)で2回洗浄し、洗浄血小板懸濁液を
1!)だ。5. EDTA was added as an anticoagulant to this rat blood.
8 mM was added and the blood was then centrifuged at 2201 for 10 minutes at room temperature to remove platelet-rich plasma).
Centrifugation was performed for 10 minutes at 1, 5 oox, and y. The platelets obtained in this state were added to a HEPES-physiological saline buffer containing 2mM EGTA (25mM HEPES, 35mM Na
Wash twice with C1, PH7, 4), and wash the washed platelet suspension 1! )is.
この洗浄血小板懸濁液と実施例乃至比較例で71Jた]
O〜1.000 )’g/m!3を加え37℃5分間
プレインキュベイジョンとした。次QこC1−”C)ア
ラキドン酸(0,05μCi、NEN製)を加えて5分
間インキュベイジョンした。 この後、キ酸を添加して
反応を停止させ、アラキドン酸代謝物を酢酸エチルで抽
出した。この抽出液を窒素気流中で乾固し、この乾固物
に少辰の酢酸エチルを加えてシリカゲルプラスチックシ
ート(MercK社製No5748)に定量的にスポッ
トし、展開した。71J with this washed platelet suspension and Examples and Comparative Examples]
O~1.000)'g/m! 3 was added for pre-incubation at 37°C for 5 minutes. Next QC1-"C) Arachidonic acid (0.05 μCi, manufactured by NEN) was added and incubated for 5 minutes. After this, phosphoric acid was added to stop the reaction, and arachidonic acid metabolites were extracted with ethyl acetate. This extract was dried in a nitrogen stream, and a small amount of ethyl acetate was added to the dried product, which was quantitatively spotted on a silica gel plastic sheet (No. 5748 manufactured by MercK) and developed.
展開溶媒はタロロポルム:メタノール:酢酸:水(90
:8 : l :0.8.溶計比)を用いた。The developing solvent was taloloporum: methanol: acetic acid: water (90%
:8 :l :0.8. molten ratio) was used.
放射活性代謝産物をオートラジオグラフで検出しそのス
ポットに対応するシリカゲルシートを切り取り液体シン
チレーションカウンターで放射活性を測定した。このよ
うな系昏こおいて主に3つのスポットが現われた。1−
ロンボサキンB 2 (TXB2 )12−ヒドロキシ
−5,8,10−ヘプタデカトリエノイック酸(HHT
)と12−ヒドロキシ−5,8゜10.14−エイコサ
テトラエノイック酸(12−1−TETE)であった。Radioactive metabolites were detected using an autoradiograph, silica gel sheets corresponding to the spots were cut out, and radioactivity was measured using a liquid scintillation counter. Three main spots appeared in such a system. 1-
Lombosaquin B2 (TXB2) 12-hydroxy-5,8,10-heptadecatrienoic acid (HHT
) and 12-hydroxy-5,8°10.14-eicosatetraenoic acid (12-1-TETE).
TXB2とHHTはアラキドン酸よりンクロオキシゲ
ナーゼを経て代謝されたものであり、l 2−HETE
は12−リボギシゲナーゼを経て代謝されたものである
。TXB2は強力な血小板凝集作用や血管収縮作用を持
つTXA2の安定な変換物である。 尚、TXB2は既
知のTXB2標準品とのTLCで同定した。また12−
HETEはそのメチルエステルのトリメチルシリル誘導
体のGLC−MSGこより同定した。TXB2 and HHT are metabolized from arachidonic acid via chromooxygenase, and l2-HETE
is metabolized via 12-ribogysigenase. TXB2 is a stable conversion product of TXA2 that has strong platelet aggregation and vasoconstriction effects. Note that TXB2 was identified by TLC with a known TXB2 standard product. Also 12-
HETE was identified from GLC-MSG of the trimethylsilyl derivative of its methyl ester.
その結果を第」表ζこまとめて記載する。The results are summarized in Table ζ.
第 1 表
中 数値は無処理を100%としてTXB の生酸量を
係で示したものである。The numerical values in Table 1 indicate the amount of raw acid in TXB, taking the value of no treatment as 100%.
試験例1
〈対 象ン
高血圧症、高脂廁症、肝炎+ ll’j尿病、不定愁訴
症候trrで高粘度血液群36例
く症 例〉
上記の病名中、高粘度群30例Q″−霊芝抽出物3g投
与、6例Qこ霊芝抽出物9g投与した。Test Example 1 <Subjects: 36 cases of high viscosity blood group with hypertension, hyperlipidemia, hepatitis + urinary disease, undefined complaint symptoms trr> Among the above diseases, 30 cases of high viscosity group Q'' - 3g of Ganoderma lucidum extract was administered, and 6 cases Q were administered 9g of Ganoderma extract.
く判 定〉
前者の霊芝抽出物3g投与ltY、は、症状の改善のみ
られるものは多く見られたが、4力月後までに、Jfn
液粘度の著明な改善のみられるものはなかった。Judgment> In the former case, 3g of Ganoderma extract was administered, many patients showed improvement in symptoms, but by 4 months, Jfn
There was no significant improvement in liquid viscosity.
後者の霊芝抽出物9g投与群では、血液粘度の著;すJ
な改善及びaリボプロティンの改善が見られた。症状改
善も著明である。In the latter group administered 9 g of Ganoderma extract, blood viscosity was significantly reduced;
Improvements in α-riboprotein were observed. Symptom improvement was also noticeable.
試験例2
〈症 例> (]) 56オ ♀ IJi:6血栓后片
マヒ4年前Qこ脳血栓の既応あり、現在右手のンビレ感
を訴えて来院され、右手三里の灸と霊芝抽出物9I74
の併用を行い、4力月後に改善した。Test Example 2 <Case> (]) 56 O ♀ IJi: 6 Hemiplegia after thrombosis 4 years ago Q. He had a history of cerebral thrombosis, and currently visited the hospital complaining of a feeling of tingling in his right hand. Moxibustion and reishi extract on his right hand. Thing 9I74
The condition improved after 4 months.
血液粘度とβリボの改善を認める。Improvements in blood viscosity and β-ribo were observed.
く症 例>(2)58才 ♀ 高血圧症、更年iJ I
重書
以前より高血圧症の既応あり。その他更年期障害の合併
を認め、特Qこ「耳がふさがる」症状に悩む。Cases > (2) 58 years old ♀ Hypertension, menopause iJ I
There was a history of hypertension prior to this report. She also has other menopausal symptoms and suffers from the symptoms of ``fullness of ears''.
霊芝抽出物9.!7/ロ服用後、1力月後に血圧が安定
し2力月後には「耳のふさがる」と言う症状も改善した
。Reishi extract9. ! After taking 7/ro, his blood pressure stabilized after one month, and his symptoms of ``fullness of ears'' improved after two months.
く症 例ン (3)高血圧症 右半身ンビレ感。 CTスキャンの険査では異常なし。(3) Hypertension Feeling of numbness on the right side of the body. A CT scan revealed no abnormalities.
霊芝抽出物1’/B処方。4カ刀後に血圧の安定が認め
られ、手の/ビレ1みも軽快した。Reishi extract 1'/B formulation. After four strokes, his blood pressure stabilized, and his hand/fin rash improved.
βリポの改善あり。There was an improvement in β-lipo.
く症 例〉(4)更年期障害 肩こり、腰痛、ひえのほせ症あり。Case example (4) Menopausal disorder I have stiff shoulders, lower back pain, and hot flashes.
体質改善が希望。I hope to improve my physical condition.
霊芝抽出物9g/日処方。1力月で血液粘度βリボの改
善を認め、症状の改善をみる。Prescription of Reishi extract 9g/day. Within 1 month, an improvement in blood viscosity and β-ribo and symptoms were observed.
〈症 例〉(5)慢性肝炎
5年前より慢性肝炎の診断 その後最低でもGOT、G
PTが50以下Gこなった事がない。<Case> (5) Chronic hepatitis Diagnosis of chronic hepatitis 5 years ago. Since then, at least GOT, G
I have never had a PT of less than 50G.
霊芝抽出物を9!/IEを処方したところ、7力月後に
GOT、GPTが50以下となり、その後半年間変化な
し。Reishi extract 9! /When I was prescribed IE, GOT and GPT became less than 50 after 7 months and remained unchanged for 6 months.
く症 例〉(6)慢性肝炎 2年前に肝炎の診断。Case example (6) Chronic hepatitis Diagnosed with hepatitis two years ago.
霊芝抽出物を91/日服用後2カ月後Oこ、検査値の改
善を;忍める。Two months after taking ganoderma extract 91 days a day, the test values improved.
血液粘度、βリポの改善あり。Blood viscosity and β-lipo levels improved.
以上の結果から明らかな如く、この発明Qこ係る食品で
使用する特定霊芝抽出物がアラキドン酸の代謝抑制能や
高粘度血液症の改善に優れた効果を有することが判る。As is clear from the above results, the specific Reishi mushroom extract used in the food according to the invention Q has an excellent effect on suppressing the metabolism of arachidonic acid and improving hyperviscosity blood disease.
Claims (1)
n)の熱水抽出物を更Q二含酸素系有機溶媒で抽出した
抽出物を必須成分とする霊芝抽出物を含有する食品。0) Ganoderma 1 icido+
A food containing a Ganoderma lucidum extract whose essential ingredient is an extract obtained by extracting the hot water extract of n) with a further oxygen-containing organic solvent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58144018A JPS6034914A (en) | 1983-08-05 | 1983-08-05 | Food containing extract of ganodema licidum |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58144018A JPS6034914A (en) | 1983-08-05 | 1983-08-05 | Food containing extract of ganodema licidum |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS6034914A true JPS6034914A (en) | 1985-02-22 |
Family
ID=15352407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58144018A Pending JPS6034914A (en) | 1983-08-05 | 1983-08-05 | Food containing extract of ganodema licidum |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6034914A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61225649A (en) * | 1985-03-29 | 1986-10-07 | Zenichi Ogita | Quality test of reishi (ganoderma) |
JPH0856613A (en) * | 1994-08-10 | 1996-03-05 | Korea Food Dev Research Inst | Antihypertensive health food and rice gruel and cut rice cake prepared by using the same as material |
CN104489638A (en) * | 2013-12-04 | 2015-04-08 | 融水苗族自治县怀宝镇富民灵芝专业合作社 | Whole-plant slicing process for lucid ganoderma |
-
1983
- 1983-08-05 JP JP58144018A patent/JPS6034914A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61225649A (en) * | 1985-03-29 | 1986-10-07 | Zenichi Ogita | Quality test of reishi (ganoderma) |
JPH0856613A (en) * | 1994-08-10 | 1996-03-05 | Korea Food Dev Research Inst | Antihypertensive health food and rice gruel and cut rice cake prepared by using the same as material |
JP2666179B2 (en) * | 1994-08-10 | 1997-10-22 | 財団法人韓國食品開發研究院 | Antihypertensive health food composition |
CN104489638A (en) * | 2013-12-04 | 2015-04-08 | 融水苗族自治县怀宝镇富民灵芝专业合作社 | Whole-plant slicing process for lucid ganoderma |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bnouham et al. | Antihyperglycemic activity of the aqueous extract of Urtica dioica | |
Ganong et al. | Evidence of secretion of an aldosterone-stimulating substance by the kidney | |
US20060233896A1 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, Cistanche tubulosa (Schenk.) Wight, process of making the same, and uses of the same | |
Wang et al. | Protective effects of Punica granatum (pomegranate) peel extract on concanavalin A-induced autoimmune hepatitis in mice | |
Zhang et al. | Antidiabetic activity of Taxus cuspidata polysaccharides in streptozotocin-induced diabetic mice | |
Pham et al. | Effects of Averrhoa carambola L.(Oxalidaceae) juice mediated on hyperglycemia, hyperlipidemia, and its influence on regulatory protein expression in the injured kidneys of streptozotocin-induced diabetic mice | |
CN114209721B (en) | Moringa oleifera leaf polyphenol-polysaccharide composition capable of reducing blood sugar and controlling lipid as well as preparation method and application of moringa oleifera leaf polyphenol-polysaccharide composition | |
JPH0516413B2 (en) | ||
JP2711630B2 (en) | External preparation for skin | |
US4918099A (en) | Drug, preparation and use thereof | |
JP5186628B2 (en) | Method for preparing medicinal composition | |
JPS6034914A (en) | Food containing extract of ganodema licidum | |
JP4822291B2 (en) | Liver fibrosis inhibitor | |
CN103923043B (en) | A method of effectively preparing tanshin polyphenolic acid B extract | |
Alexopoulos et al. | Role of green tea in reduction of cardiovascular risk factors | |
JP2002205949A (en) | Method for ameliorating dysbolism and composition therefor | |
CN110201025B (en) | Application of cyclocarya paliurus extract in preparation of medicine for treating or preventing diabetic cardiomyopathy | |
CN103989752B (en) | A kind of for preventing, treat the pharmaceutical composition of Diabetes with Hypertension | |
EP1498131B1 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from Cistanche tubulosa | |
JP4643936B2 (en) | Thrombosis ameliorating agent | |
JP2008214246A (en) | Age production inhibitor and method for producing the same | |
JP2003518071A (en) | Pharmaceuticals manufactured from aged key extract | |
CN113577147B (en) | Medicinal total flavone and its preparation method and medicinal use | |
CN116693711B (en) | Polygonum multiflorum polysaccharide, extraction method and application thereof | |
JPH0529015B2 (en) |